For the first time in the 120-year history of Alzheimer's disease research, American doctors can offer patients something that was once considered impossible: treatments that measurably slow the progression of the disease itself. As of 2026, two FDA-approved disease-modifying therapies are being administered to thousands of patients across the United States. The research pipeline contains more drug candidates than at any prior point in history. And the field is beginning to ask a question that would have seemed fantastical a decade ago: can Alzheimer's be prevented?
"The current Alzheimer's disease treatment landscape is the most exciting in the field's history," said Dr. Parichita Choudhury, MD, cognitive neurologist and associate director of the memory clinic at Banner Sun Health Research Institute, speaking at the 2026 American Academy of Neurology Annual Meeting.
